Physician profile
Jerome Watson
NPI 1336144138
$15,275.29
in general payments reported to CMS, 2019-2025
62 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 93% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $1,656 · 2021: $2,295 · 2022: $2,518 · 2023: $2,717 · 2024: $2,519 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,037 · Entertainment: $13.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,037.44 |
| Entertainment | $13.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,911.66 | 2019-2025 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,680.11 | 2019-2025 | |
| Abbvie INC. | $1,656.49 | 2019-2024 | Ubrelvy, Qulipta |
| Janssen Biotech, INC. | $1,340.85 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $924.91 | 2019-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $868.71 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $645.68 | 2019-2025 | Tymlos |
| Collegium Pharmaceutical, INC. | $457.07 | 2022-2025 | Belbuca, Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.50 | 2019-2024 | Ofev |
| Pfizer INC. | $385.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $378.95 | 2019-2022 | |
| Octapharma USA, INC. | $313.01 | 2023 | Octagam Immune Globulin (Human) |
| Tersera Therapeutics LLC | $211.03 | 2021-2025 | Quzyttir |
| Mallinckrodt Hospital Products INC. | $206.25 | 2023-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $171.50 | 2021-2023 | Lupkynis |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.